Funko Inc vs Eli Lilly And Co — how do they compare? Funko Inc trades at $5.75 (market cap $315.21M), while Eli Lilly And Co trades at $1,176.79 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 3267.7× Funko Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | LLY | |
|---|---|---|
Market Cap | $315.21M | $1.03T |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $1.24K |
52-Week Low | $2.46 | $625.65 |
Enterprise Value | $560.25M | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.55, down 2.46% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/S ratio of 0.34 and strong gross margins near 40%, but negative net income and ROE. Recent quarters have seen earnings beats against expectations, and analyst sentiment leans positive with a 42.86% buy rating and no sell recommendations. News highlights new product launches and a strong Q1 2026 report.
The outlook balances product-driven revenue potential against persistent profitability challenges. Investment opportunity lies in the low valuation multiple and recent earnings momentum, but risks include sustained negative margins, high debt levels, and volatile cash flows from operations.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →